Coya Therapeutics reported QQ1 2025 results with a modest revenue base and a substantial operating burn focused on R&D and general & administrative activities. Revenue totaled $0.258 million, yielding a gross profit of $0.258 million and a gross margin of 100% due to the absence of cost of revenue. The company’s operating expenses were $7.934 million (R&D $5.214 million; G&A $2.714 million), producing an EBITDA of -$7.67 million and an operating loss of -$7.68 million. Net income came in at -$7.31 million, with an EPS of -$0.44 for the quarter. These figures reflect a typical early-stage biotech profile: meaningful R&D investment ahead of product approvals, with no current product revenue.
Cash flow remained negative from operations at -$2.83 million for the quarter, while financing activity contributed only $0.019 million. The net cash position declined by about $2.81 million in the quarter, leaving cash and equivalents at $35.53 million at period-end. The balance sheet shows a strong liquidity position for a clinical-stage company, with total current assets of $38.37 million against total current liabilities of $4.34 million and no long-term debt. The cash runway, based on the quarterly operating cash burn, suggests funding headroom for roughly 3–4 years under current cash burn assumptions, though this is highly sensitive to trial timelines, clinical milestones, and potential dilution events.
From a development perspective, Coya remains focused on its regulatory T cell (Treg) platform, including COYA-101 (autologous Treg product) with Phase 2a data in ALS, and IND-enabling COYA-301 and COYA-302 programs, plus preclinical COYA-201 and discovery COYA-206 candidates. Absent explicit management guidance in the QQ1 release, the key near-term catalysts are pipeline milestones and any partnering discussions that could help monetize the platform. Overall, the investment case hinges on successful clinical readouts and timely advancement of the pipeline against a backdrop of continued cash burn and high R&D intensity.